MP25-12 PREDICTORS OF MAJOR COMPLICATIONS AFTER CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA: INSIGHTS FROM A RETROSPECTIVE MULTICENTRE REGISTRY
Riccardo Campi,Maximilian C. Kriegmair,Riccardo Bertolo,Tobias Klatte,Jose Rubio,Tobias Maurer,Siska Van Bruwaene,Estefania Linares,Vital Hevia,Mireia Musquera,Ithaar Derweesh,Georgi Guruli,Eduard Rousel,Maarteen Albertsen,Nicola Pavan,Francesco Claps,Alessandro Antonelli,Shudong Zhang,Lulin Ma,Riccardo Autorino,Francesco Porpiglia,Umberto Capitanio,Andrea Minervini,Maria Carmen Mir
DOI: https://doi.org/10.1097/01.ju.0000555657.73709.84
2019-01-01
Abstract:You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) II (MP25)1 Apr 2019MP25-12 PREDICTORS OF MAJOR COMPLICATIONS AFTER CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA: INSIGHTS FROM A RETROSPECTIVE MULTICENTRE REGISTRY Riccardo Campi*, Maximilian C. Kriegmair, Riccardo Bertolo, Tobias Klatte, Jose Rubio, Tobias Maurer, Siska Van Bruwaene, Estefania Linares, Vital Hevia, Mireia Musquera, Ithaar Derweesh, Georgi Guruli, Eduard Rousel, Maarteen Albertsen, Nicola Pavan, Francesco Claps, Alessandro Antonelli, Shudong Zhang, Lulin Ma, Riccardo Autorino, Francesco Porpiglia, Umberto Capitanio, Andrea Minervini, and Maria Carmen Mir Riccardo Campi*Riccardo Campi* More articles by this author , Maximilian C. KriegmairMaximilian C. Kriegmair More articles by this author , Riccardo BertoloRiccardo Bertolo More articles by this author , Tobias KlatteTobias Klatte More articles by this author , Jose RubioJose Rubio More articles by this author , Tobias MaurerTobias Maurer More articles by this author , Siska Van BruwaeneSiska Van Bruwaene More articles by this author , Estefania LinaresEstefania Linares More articles by this author , Vital HeviaVital Hevia More articles by this author , Mireia MusqueraMireia Musquera More articles by this author , Ithaar DerweeshIthaar Derweesh More articles by this author , Georgi GuruliGeorgi Guruli More articles by this author , Eduard RouselEduard Rousel More articles by this author , Maarteen AlbertsenMaarteen Albertsen More articles by this author , Nicola PavanNicola Pavan More articles by this author , Francesco ClapsFrancesco Claps More articles by this author , Alessandro AntonelliAlessandro Antonelli More articles by this author , Shudong ZhangShudong Zhang More articles by this author , Lulin MaLulin Ma More articles by this author , Riccardo AutorinoRiccardo Autorino More articles by this author , Francesco PorpigliaFrancesco Porpiglia More articles by this author , Umberto CapitanioUmberto Capitanio More articles by this author , Andrea MinerviniAndrea Minervini More articles by this author , and Maria Carmen MirMaria Carmen Mir More articles by this author View All Author Informationhttps://doi.org/10.1097/01.JU.0000555657.73709.84AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVES: The role of cytoreductive nephrectomy (CN) in the setting of metastatic renal cell carcinoma (mRCC) is still object of great debate within the Urology community. In this regard, assessing the harms of CN is key to select patients most likely to benefit from this procedure. The aim of the study was to evaluate potential predictors of major complications (MC) after CN in a multicentre international cohort of patients with mRCC. METHODS: Data from patients with mRCC undergoing CN at 11 centers included in the REgistry of MetAstatic RCC (REMARCC) from January 2014 to December 2017 were retrospectively collected and analyzed. Patients with complete data on comorbidity profiles, intraoperative outcomes and perioperative complications formed the analytic cohort. Postoperative complications were assessed and graded using the modified Clavien-Dindo scale. MCs were defined as Clavien-Dindo grade 3 or more. Multivariable logistic regression analysiswas used to assess potential clinical predictors of 30-day readmission. RESULTS: Overall, 374 patients were included in the study. Twenty-three patients (6.1%) experienced MCs. Patient age, sex, BMI, Charlson comorbidity index, ECOG performance status, baseline Hb levels, estimated glomerular filtration rate, cT and cN status, as well as location of metastatic lesions, were comparable among patients who did and did not experience MCs. Conversely, median tumor size was significantly higher in patients experiencing MCs (11.0 vs 8.5 cm, p=0.002). Surgical approach was significantly different in the two study groups (87.0% of patients who experienced MCs were treated with open CN as compared to 65.4% of patients who did not; p=0.034). Performance of LDN was comparable among the study groups; on the contrary, removal of adjacent organs (43.5 % vs 23.4%, p=0.03), renal vein/vena cava thrombectomy (43.5% vs 17.4%, p=0.002) and metastasectomy at the time of CN (21.7% vs 7.1%, p=0.012) were significantly higher in patients who experienced MCs. Rate of hospital readmission within 30 days after surgery was significantly higher in patients who experienced MCs (11.1% vs 6.7%, p<0.0001), as well as length of hospitalization (14 vs 7 days, p=0.003). pT status was also significantly different among the study groups (p=0.014). At multivariable analysis, increasing tumor size, performance of metastasectomy at the time of CN and of renal vein/vena cava thrombectomy were found to be significantly associated with MCs in our study cohort. CONCLUSIONS: Performance of metastasectomy and need for renal vein/vena cava thrombectomy may significantly impact on the risk of major complications after CN and should be carefully considered in the preoperative surgical planning. The main study limitation is the retrospective design with risk of selection and attrition bias. Source of Funding: none Florence, Italy; Mannheim, Germany; Cleveland, OH; Bournemouth, United Kingdom; Valencia, Spain; Munich, Germany; Kortrijk, Belgium; Madrid, Spain; Barcellona, Spain; Louisiana Jolla, CA; Richmond, VA; Leuven, Belgium; Trieste, Italy; Brescia, Italy; Beijing, China, People’s Republic of; Richmond, VA; Torino, Italy; Milano, Italy; Firenze, Italy; Valencia, Spain© 2019 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 201Issue Supplement 4April 2019Page: e347-e347 Advertisement Copyright & Permissions© 2019 by American Urological Association Education and Research, Inc.MetricsAuthor Information Riccardo Campi* More articles by this author Maximilian C. Kriegmair More articles by this author Riccardo Bertolo More articles by this author Tobias Klatte More articles by this author Jose Rubio More articles by this author Tobias Maurer More articles by this author Siska Van Bruwaene More articles by this author Estefania Linares More articles by this author Vital Hevia More articles by this author Mireia Musquera More articles by this author Ithaar Derweesh More articles by this author Georgi Guruli More articles by this author Eduard Rousel More articles by this author Maarteen Albertsen More articles by this author Nicola Pavan More articles by this author Francesco Claps More articles by this author Alessandro Antonelli More articles by this author Shudong Zhang More articles by this author Lulin Ma More articles by this author Riccardo Autorino More articles by this author Francesco Porpiglia More articles by this author Umberto Capitanio More articles by this author Andrea Minervini More articles by this author Maria Carmen Mir More articles by this author Expand All Advertisement PDF downloadLoading ...